Eltrombopag

證據等級: L5

預測適應症: 1 個

Eltrombopag: From Immune Thrombocytopenia to HIV Infectious Disease

One-Sentence Summary

Eltrombopag is a thrombopoietin receptor agonist (TPO-RA) approved in multiple countries for chronic immune thrombocytopenia (ITP), severe aplastic anemia, and thrombocytopenia associated with chronic hepatitis C infection. The TxGNN model predicts it may be effective for HIV infectious disease, with 5 clinical trials and 10 publications currently supporting this direction — primarily centered on the management of HIV-associated thrombocytopenia and emerging evidence of direct antiviral activity.

Quick Overview

Item	Content
Original Indication	Immune thrombocytopenia (ITP); thrombocytopenia in chronic hepatitis C (globally approved; no India registration)
Predicted New Indication	HIV Infectious Disease
TxGNN Prediction Score	99.26%
Evidence Level	L3
India Market Status	✗ Not Marketed
Number of Registrations	0
Recommended Decision	Hold

Why is This Prediction Reasonable?

Currently, detailed mechanism of action data is not available in this Evidence Pack. Based on established pharmacology, Eltrombopag is a small-molecule TPO receptor agonist — it binds the transmembrane domain of the thrombopoietin receptor (c-Mpl) on bone marrow progenitor cells, stimulating platelet production independent of endogenous TPO. It is approved globally (under the brand names Promacta and Revolade) for chronic ITP and aplastic anemia, and was previously approved for thrombocytopenia in hepatitis C patients to facilitate antiviral therapy.

The mechanistic link to HIV infectious disease is twofold. First, HIV infection is a well-recognised cause of secondary immune thrombocytopenia (HIV-ITP), arising through molecular mimicry, direct megakaryocyte infection, and immune-mediated platelet destruction. Managing thrombocytopenia is clinically important in HIV patients — severe thrombocytopenia impairs the ability to administer antiretroviral and other therapies. Eltrombopag’s proven ability to raise platelet counts in both ITP and HCV-related thrombocytopenia makes it mechanistically plausible for HIV-ITP management.

Second, and more provocatively, a 2020 screen of FDA-approved drugs (PMID 32977702) identified eltrombopag as a modulator of HIV-1 proviral transcription, suggesting a potential direct role in HIV latency reversal or suppression — a mechanism entirely distinct from platelet stimulation. Case reports (PMID 25333665) have additionally documented immunomodulatory effects of eltrombopag in HIV patients, including reductions in pro-inflammatory T helper cells (Th1/Th17) and improved T-regulatory cell ratios. Taken together, these lines of evidence give the TxGNN prediction a biologically credible foundation, though direct clinical confirmation for HIV as a primary indication is still lacking.

Clinical Trial Evidence

Note: The 5 identified trials studied eltrombopag in hepatitis C-related or chronic liver disease thrombocytopenia — not HIV directly. These are presented as mechanistically relevant indirect evidence, as the thrombocytopenia management rationale transfers across infectious disease contexts.

Trial Number	Phase	Status	Enrollment	Key Findings
NCT00516321	Phase 3	Completed	687	Eltrombopag vs. placebo in HCV-thrombocytopenic patients initiating peginterferon alfa-2a + ribavirin; primary endpoint: sustained virological response supported by platelet maintenance
NCT00529568	Phase 3	Completed	759	Parallel Phase 3 study with peginterferon alfa-2b arm; assessed eltrombopag’s ability to reduce antiviral dose reductions and therapy discontinuation due to thrombocytopenia
NCT00996216	Phase 3	Completed	27	Open-label rollover study assessing long-term safety and tolerability of eltrombopag in HCV-thrombocytopenic patients who had completed prior eltrombopag studies
NCT01636778	Phase 2	Completed	45	Eltrombopag in HCV with compensated liver cirrhosis (platelets <80,000/μL); assessed platelet raising and maintenance to allow pegIFN + ribavirin initiation
NCT00678587	Phase 3	Terminated	292	Eltrombopag to reduce platelet transfusion need in chronic liver disease patients undergoing invasive procedures; terminated early — results limited

Literature Evidence

PMID	Year	Type	Journal	Key Findings
32977702	2020	Screen study	Viruses	FDA-approved drug library screen identified eltrombopag as a modulator of HIV-1 proviral transcription — suggests a potential direct antiviral mechanism beyond platelet stimulation
25504472	2015	Case series	J Int Assoc Provid AIDS Care	Initial experience using TPO-RAs (eltrombopag and romiplostim) as salvage therapy in refractory HIV-associated ITP; eltrombopag effective in several patients with optimal HAART
25333665	2014	Case report	AIDS	First reported successful eltrombopag treatment of severe aplastic anemia associated with HIV infection; eltrombopag induced trilineage haematological response with immunomodulatory effects (↓Th1/Th17, ↑Treg)
22992580	2012	Case report	AIDS	Successful use of eltrombopag without splenectomy in refractory HIV-related immune reconstitution thrombocytopenia — demonstrates clinical utility in HIV-specific context
22185370	2012	Observational	Platelets	Danish real-world experience with TPO-RAs including off-label use; secondary ITP cohort included HIV-related cases responding to eltrombopag
19932434	2009	Review	Hematol Oncol Clin North Am	Comprehensive review of infectious causes of chronic ITP including HCV, HIV, and H. pylori; establishes HIV-ITP as a distinct secondary ITP subtype amenable to TPO-RA therapy
19245929	2009	Review	Semin Hematol	Reviews therapeutic strategies for infection-related thrombocytopenias; discusses role of eltrombopag in HCV- and HIV-related ITP management
24816314	2014	Observational	Intern Med J	TPO-RA use in ITP of <6 months duration; includes HIV-associated ITP patients demonstrating platelet response
28043314	2016	Case report	J Coll Physicians Surg Pak	Hepatitis B-associated megaloblastic anemia with severe thrombocytopenia — contextual evidence for viral infection-associated thrombocytopenia requiring intervention
24128106	2013	Case report	Farm Hosp	Eltrombopag for thrombocytopenia in chronic hepatitis C patients; supporting evidence for infection-context TPO-RA efficacy

India Market Information

Eltrombopag currently has no approved registrations in India (CDSCO). The drug is not marketed under any brand name in the Indian market at the time of this report (data cutoff: 2026-04-04). Market entry would require a fresh CDSCO new drug application (NDA) submission.

For reference, eltrombopag is marketed globally as Promacta (Novartis, USA) and Revolade (Novartis, EU/other markets) with approved indications including chronic ITP, severe aplastic anemia, and HCV-associated thrombocytopenia in eligible markets.

Safety Considerations

Formal package insert warnings and contraindications were not retrievable from the India regulatory database (drug not approved). Please refer to the US FDA or EMA prescribing information for Promacta/Revolade for complete safety data.

Drug Interactions (135 interactions identified):

Eltrombopag is known to chelate polyvalent cations, significantly reducing its own oral bioavailability. The following interaction classes are clinically important:

Severity	Drug Class / Examples	Clinical Implication
Major	Eluxadoline	Avoid combination; mechanism not fully characterised but risk of serious adverse event
Moderate	Calcium salts (carbonate, citrate, gluconate, lactate, phosphate, glubionate, acetate)	Polyvalent cation chelation reduces eltrombopag absorption; separate administration by ≥4 hours
Moderate	Magnesium salts (oxide, hydroxide, carbonate, chloride, citrate, gluconate)	Same chelation mechanism; maintain dosing interval
Moderate	Aluminium hydroxide, Attapulgite, Kaolin, Magaldrate	Antacid/adsorbent interactions; separate by ≥4 hours
Moderate	Iron	Reduces eltrombopag and iron absorption mutually; separate by ≥4 hours
Moderate	Glyburide	Eltrombopag inhibits OATP1B1; may increase glyburide exposure — monitor for hypoglycaemia

Conclusion and Next Steps

Decision: Hold

Rationale: Eltrombopag has credible mechanistic and indirect clinical evidence supporting its use in HIV-associated thrombocytopenia — a complication of HIV infectious disease — and emerging (though early-stage) evidence of a direct effect on HIV-1 proviral transcription. However, there are no clinical trials specifically designed to test eltrombopag in HIV infectious disease as a primary indication, the drug is not approved in India, and the current evidence base (case reports, observational studies, and one drug screen) does not yet meet the threshold to justify a direct repurposing investment at this time.

To proceed, the following is needed:

MOA confirmation: Retrieve full DrugBank mechanism-of-action data to formally characterise the relationship between TPO-RA stimulation and HIV pathophysiology
India regulatory pathway: Assess CDSCO requirements for new drug application or bridging study given the drug’s approved status in other jurisdictions
Indication clarification: Determine whether the target indication is (a) HIV-associated thrombocytopenia (secondary indication, narrower but stronger evidence) or (b) HIV infectious disease broadly (higher bar, requires Phase 2/3 trial data)
Clinical trial design: If pursuing HIV-ITP specifically, a small Phase 2 open-label study in HIV-positive patients with refractory thrombocytopenia would be the logical next step
Package insert review: Retrieve and review TFDA/FDA prescribing information PDF to complete the safety gap (DG001) before any clinical planning proceeds
YMYL disclaimer: All outputs must include the standard disclaimer — “For research reference only; not a substitute for medical advice. Repurposing candidates require clinical validation before use.”
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.